S. Harari (Milan, Italy), E. Fireman (Tel-Aviv, Israel)
LH-RH agonists are not useful in treatment for LAM
R. Cassandro, L. Longo, A. Caminati, M. Mirenda, G. Paciocco, S. Harari (Milan, Italy)
|  |
Incidence and prevalence of interstitial lung diseases in Greece
A. Karakatsani, D. Papakosta, A. Rapti, M. Dimadi, A. Markopoulou, P. Latsi, V. Polychronopoulos, G. Birba, E. Serasli, A. Antoniou, A. Papagiannis, C. H. Labrakis, I. Pappa, S. Katsiboula, D. Bouros (Athens, Greece)
| |
Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide
S. Dass, C. Fernandes, B. Griffiths, P. Emery, M. T. Henry (Leeds, United Kingdom)
| |
Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis
S. T. Uh, Y. K. Kim, K. U. Kim, G. I. Lim, D. J. Na, Y. T. Chung (Seoul, Daejeon, Republic Of Korea)
| |
CD34, VCAM-1, E-Selectin and ICAM-1 expression in major types of idiopathic interstitial pneumonia
E. R. Parra, L. R. da Costa, A. M. Ab‘Saber, C. R. de Carvalho, R. A. Kairalla, V. L. Capelozzi (Sao Paulo, Brazil)
| |
Transforming growth factor-β1 gene polymorphism and susceptibility to idiopathic pulmonary fibrosis
M. K. Byun, M. S. Park, Y. S. Chang, W. Y. Chung, C. H. Hahn, S. M. Kang, J. W. Moon, Y. S. Kim, S. K. Kim, J. Chang, S. K. Kim, S. H. Cho, H. L. Lee (Seoul, Incheon, Republic Of Korea)
| |
Diffuse alveolar hemorrhage and pulmonary fibrosis in MPO-ANCA-associated vasculitides
S. Homma, A. Miyamoto, H. Takaya, M. Kawabata, K. Kishi, E. Tsuboi, K. Yoshimura, N. Motoi (Tokyo, Japan)
| |
Decreased levels of CXC angiogenic chemokines (IL-8, ENA-78 and GRO-α) in BALF after interferon gamma-1b treatment in IPF patients
K. M. Antoniou, E. G. Tzortzaki, N. Tzanakis, K. Sfiridaki, E. L. Kandidaki, M. Alexandrakis, D. Moraitaki, G. Maltezakis, D. Bouros, N. Siafakas (Heraklion, Alexandroupolis, Greece)
| |
Expression of Smad proteins during myofibroblast differentiation in pulmonary fibrosis
J. Usuki, K. Matsuda, A. Azuma, S. Kudoh (Tokyo, Japan)
| |
Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis
M. Hecker, J. K. Jagielska, N. Büchner, U. Seay, W. Klepetko, W. Seeger, O. Eickelberg (Giessen, Germany; Vienna, Austria)
| |
Abstract organizing pneumonia: nationwide epidemiological study
O. Sveinsson, H. Isaksson, G. Gudmundsson (Reykjavik, Iceland)
| |
Outcomes in interstitial lung diseases (ILDs)
R. Carbone, F. Montanaro, G. Bottino (Genoa, Italy; Locarno, Switzerland)
| |
Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension
I. van der Lee, P. Zanen, J. C. Grutters, R. J. Snijder, J. M. van den Bosch (Nieuwegein, Netherlands)
| |
Induced sputum (IS) angiogenic cytokines in patients with sarcoidosis (SA)
E. Fireman, D. Gilburd, J. Greif, M. Topilsky (Tel-Aviv, Israel)
| |
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
L. Debevec, A. Stadler, J. Salomon, T. Geiser, L. P. Nicod (Bern, Switzerland)
| |
C-C chemokine receptor 2 gene polymorphism V64I and CCR2 expression on T lymphocytes in pulmonary sarcoidosis patients
A. Krol, R. Kieszko, S. Chocholska, P. Krawczyk, M. Michnar, J. Milanowski (Lublin, Poland)
| |
Combination of pentoxifylline and steroids in sarcoidosis treatment
H. L. Baradzina, I. L. Kotovich, A. D. Tahanovich, N. V. Petyovka (Minsk, Belarus)
| |
Identification of a chromosome location linked to pulmonary alveolar microlithiasis (PAM)
H. Qun, S. Izumi, H. Miyazawa, B. Uchiyama, S. Tanaka, T. Ishida, Y. Nagai, T. Tanaka, S. Fukuyama, R. Tazawa, M. Kanazawa, K. Yoshimura, T. Tachibana, K. Kudoh, T. Nukiwa, K. Hagiwara (Moroyama, Japan)
| |